Back to top
more

AZURRX BIOPHARM (AZRX)

(Delayed Data from NSDQ)

$2.55 USD

2.55
68,693

+0.05 (2.11%)

Updated May 3, 2019 03:59 PM ET

After-Market: $2.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Entero Therapeutics, Inc. [AZRX]

Reports for Purchase

Showing records 81 - 100 ( 134 total )

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 81

08/19/2019

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 82

08/15/2019

Company Report

Pages: 9

Five Pills or 35, Which Would You Prefer?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 83

08/14/2019

Company Report

Pages: 6

2Q19 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 84

08/14/2019

Company Report

Pages: 7

Phase 2 Data Expected in September; Q2 Results Reported

Provider: Roth Capital Partners, Inc.

Analyst: ISAACSON J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 85

08/14/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 86

08/11/2019

Company Report

Pages: 9

Five Pills or 35, Which Would You Prefer?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 87

07/29/2019

Company Report

Pages: 6

Phase 2 Data in Cystic Fibrosis with EPI Available Soon; Financing Complete; Reiterate Buy; Modulating Target to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 88

07/11/2019

Company Report

Pages: 14

Five Pills or 35, Which Would You Prefer?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 50.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 89

07/09/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 90

07/09/2019

Company Report

Pages: 6

New Phase 2 Trial Announced for CF Patients with Severe EPI

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 91

05/24/2019

Company Report

Pages: 5

Phase 2 Study in Cystic Fibrosis Patients Reaches Enrollment Target; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 92

05/21/2019

Company Report

Pages: 6

New Secondary Endpoint Data in Phase 2a Study Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 93

05/20/2019

Company Report

Pages: 7

Price: 24.95

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 94

04/24/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 95

04/24/2019

Company Report

Pages: 5

Phase 2 Study Enrollment Reaches Halfway Mark; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 96

04/23/2019

Company Report

Pages: 6

Phase 2 OPTION Trial 50% Enrolled

Provider: Roth Capital Partners, Inc.

Analyst: ISAACSON J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 97

04/18/2019

Company Report

Pages: 6

Financing Completed; MS1819 Rights Purchased; Reiterate Buy and Lowering Price Target to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 98

04/04/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 99

04/04/2019

Company Report

Pages: 7

Price: 24.95

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 100

04/03/2019

Company Report

Pages: 6

Annual Results Announced - Enrollment on Track for Phase 2 CF Trial

Provider: Roth Capital Partners, Inc.

Analyst: ISAACSON J

Price: 25.00

Research Provided by a Third Party
// eof